Predicting Pandemics: Mobilizing an Active Global Surveillance System

Rapid Scientific Progress vs. Systemic Gaps

• Viral genomic sequencing speed improved dramatically compared to prior outbreaks:
  • SARS (2003): 149 days to partial sequence.
  • Swine Flu (2009): 77 days to partial sequence.
  • COVID-19 (2020): 12 days to full sequence publication.
• Despite speed in data sharing (e.g., vaccine R&D starting Jan 11 using published sequences), experts note a critical failure in global pathogen surveillance infrastructure.
• No global system currently exists to identify novel pathogens, antimicrobial resistance, or bioterrorist attacks in real-time anywhere in the world.
• The discovery of early US cases by accident (via a flu sequencing project in Seattle) highlighted the unacceptable reliance on serendipity rather than proactive networks.

Distinctions in Testing and Surveillance

• Surveillance: Identifies if an outbreak exists, determines the pathogen, maps transmission routes (local vs. imported), and tracks mutations to ensure test/therapy efficacy.
• Diagnostic Testing: Provides a binary "yes/no" result for symptomatic individuals to guide clinical care.
• Screening: Tests asymptomatic populations (e.g., returning to work/school) to prevent spread.
• Research: Investigates severity variance and identifies targets for new therapies and vaccines using viral genome data.
• Francis D'Souza (Illumina) reported that their sequencing-based diagnostic product moved from design to FDA clearance in approximately 60 days, a pace unprecedented for diagnostic development.

Global and US Surveillance Failures

• The US response was hampered by slow detection, delayed testing infrastructure, and a lack of a clear national testing and containment plan.
• South Korea is cited as a contrast, mobilizing national leadership, massive testing, and contact tracing within 24 hours of detecting the first case alongside the US.
• Africa entered the pandemic with zero domestic diagnostic capacity; by end-March, only three countries had the capability, compared to over 800 labs today.
• Francis D'Souza announced a new "Africa Pathogen Genomics Initiative," a $100 million, four-year partnership with the African CDC and Bill & Melinda Gates Foundation to install sequencing capacity in 20 countries.
• Dr. John Nkengasong (Africa CDC) noted that while capacity is growing, the continent still lacks the means to locally develop diagnostics despite having the genomic knowledge to do so.

The Need for a "One Health" Approach

• Experts advocate for integrating human, animal, and environmental health surveillance to address zoonotic spillover events.
• Most emerging diseases originate in animal populations due to factors like wet markets, bushmeat consumption, and encroachment on natural habitats.
• Surveillance systems should expand beyond clinical data to include syndromic monitoring (e.g., media reports, Google searches, OTC medication sales) and environmental sampling (e.g., sewage systems).
• Existing global frameworks for disease surveillance exist but remain chronically underfunded and have not integrated modern genomic technologies.

Political Challenges and Future Commitments

• Dr. Hamburg expressed concern over US withdrawal from the WHO and strained global alliances, noting that a pandemic cannot be contained within national borders.
• Despite geopolitical tensions (e.g., US-China), scientific collaboration continues via open-source platforms like GISAID, where tens of thousands of viral genomes are shared globally.
• Francis D'Souza and Dr. Hamburg both identified the creation of a sustainable public-private partnership as the single most critical step to plug surveillance gaps.
• Proposed models suggest an economic structure with subscribers (governments, defense, enterprises) to ensure self-sustaining funding for continuous global monitoring.
• Dr. Hamburg emphasized the need for a system of incentives, rewards, and accountability to ensure nations meet minimum surveillance standards and long-term preparedness goals.